KAILERA Therapeutics IPO

Develops innovative therapies for obesity and related conditions to enhance patient health and quality of life.

NASDAQ: KLRA

Buy

Buy Private Stock

Sign up to invest in private companies like KAILERA Therapeutics before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like KAILERA Therapeutics before their IPO.

Overview

KAILERA Therapeutics completed their IPO on April 17, 2026. Now that KAILERA Therapeutics is a public company, Nasdaq Private Market does not actively track its performance. The data below is for reference before the company’s IPO.

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promising clinical results in early trials. By advancing these therapies, Kailera seeks to offer patients effective treatment options that enhance health and quality of life.

Sector

Healthcare & Life Sciences

Founded

2024

Headquarters

Waltham, MA

KAILERA Therapeutics Funding

KAILERA Therapeutics Funding History Pre-IPO

Gain insights into KAILERA Therapeutics funding history prior to their IPO, including the funding round, time period, and amount raised.

Financing Round Date Amount Price per share Valuation
Round Date Amount PPS Valuation
Series A Oct 01, 2024 357M
XXXXX
XXXXX

Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market

Buy

Buy Private Stock

Sign up to invest in private companies like KAILERA Therapeutics before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like KAILERA Therapeutics before their IPO.

KAILERA Therapeutics Management Team

KAILERA Therapeutics people and management – Prior to IPO

  • CEO, President, Board Member
    Ron Renaud
  • COO, Chief Business Officer
    Paul Burgess
  • Board Member
    John F. Milligan
  • Board Member
    Andrew Kaplan
  • Chief Medical Officer
    Scott Wasserman
  • Chief Legal Officer
    Scott Akamine
  • Board Member
    Michael Gladstone
  • Board Member
    Adam Koppel
  • Board Member
    Christopher Hite
  • Board Member
    Amir Zamani
  • CTO
    Doug Bakan
  • Chief Commercial Officer
    Jamie Coleman
  • Chief People Officer
    Paula Cloghessy

Investors

Major KAILERA Therapeutics investors

  • Atlas Venture Advisors

  • Lyra Capital

  • Royalty Pharma

  • RTW Investments

  • Adage Capital Management

  • CPP Investments

  • Janus Henderson

  • Qatar Investment Authority (QIA)

  • Bain Capital Ventures

  • Invus Group

KAILERA Therapeutics Valuations & Financials

Looking for private company valuations and share price data?

Nasdaq Private Market Data & Intelligence is the private company valuation database covering 4,000+ venture-backed companies with daily pricing, financing history, and secondary market activity. View real-time NPM data on pre-IPO companies including valuations, private company comparable transactions, and historical share price information — the private company due diligence data sources institutional investors rely on.

Similar Companies

Explore companies

like KAILERA Therapeutics

  • Cedar Inc-Logo

    Cedar

    Healthcare & Life Sciences

    The tech platform uses modern intelligence to improve healthcare financial experiences for everyone.

  • Weareresilience-Logo

    Resilience

    Healthcare & Life Sciences

    Operates as technology-focused biomanufacturing company dedicated to broadening access to complex medicines.

  • Virta Health-Logo

    Virta Health

    Healthcare & Life Sciences

    Online specialty medical clinic focused on reversing type 2 diabetes.

  • Elligo Health Research

    Healthcare & Life Sciences

    Connects healthcare sites, sponsors, and patients to streamline clinical trial access through technology and data-driven solutions.

  • Droplet Biosciences

    Healthcare & Life Sciences

    Turning surgical drain fluid into powerful, early molecular insights to guide personalized post-surgery cancer care.

  • Hinge Health-Logo

    Hinge Health

    Healthcare & Life Sciences

    Digital clinic for back, joint, and muscle pain.

  • Eikon Therapeutics Inc-Logo

    Eikon Therapeutics

    Healthcare & Life Sciences

    Uses revolutionary technology to discover novel treatments for life-threatening diseases.

  • Insitro-Logo

    insitro

    Healthcare & Life Sciences

    Drug discovery and development company.

  • Cerebral

    Healthcare & Life Sciences

    Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.

FAQ

Questions?

We have answers

Buy KAILERA Therapeutics Stock

KAILERA Therapeutics became publicly traded following its IPO on April 17, 2026, its shares now trade on public stock exchanges under the ticker symbol NASDAQ: KLRA. Before the IPO, KAILERA Therapeutics stock was privately held and available only through private market transactions.

If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.

Sell KAILERA Therapeutics Stock

Following its IPO on April 17, 2026, KAILERA Therapeutics shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.

If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.

 

KAILERA Therapeutics Stock Price

Following the IPO, KAILERA Therapeutics stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching KAILERA Therapeutics’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.

KAILERA Therapeutics Stock Ticker Symbol

Following its IPO on April 17, 2026, KAILERA Therapeutics stock now trades on public markets under the ticker symbol NASDAQ: KLRA. You can view real-time stock information through widely used financial data platforms.

Criteria to Sell KAILERA Therapeutics Stock

Following the KAILERA Therapeutics IPO, public shares can be sold through any brokerage.

Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

 

Criteria to Buy or Invest in KAILERA Therapeutics Stock

Following KAILERA Therapeutics’s initial public offering on April 17, 2026, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying KAILERA Therapeutics stock can do so through their preferred broker, just as they would with any other publicly traded security.

Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

KAILERA Therapeutics Stock Settlement

Since KAILERA Therapeutics is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.

Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

KAILERA Therapeutics IPO

KAILERA Therapeutics completed its IPO on April 17, 2026, and is now publicly available through major financial sources.